Computational drug discovery platform for biosimulation and molecular modeling
Deep Origin builds cloud software for computational drug discovery, pairing a TypeScript/React product layer with a scientific core of GROMACS, RDKit, PyTorch and Slurm on AWS EKS. That HPC-plus-SaaS stack, alongside current hiring for senior product and director-level roles, points to a company formalizing its product organization while pushing generative models into the platform.
Deep Origin is a South San Francisco company founded in 2022 that develops software for drug discovery research, covering bioinformatics, biosimulation, data management and small-molecule work. Its platform runs on AWS with Kubernetes, Terraform and Slurm, supporting molecular simulation and cheminformatics tools such as GROMACS, RDKit and PyMOL. The company also pursues scientific and drug discovery partnerships. It is privately held, has 51–200 employees, and hires in the United States and Armenia.
Deep Origin uses React, TypeScript, Node.js, Python, Go and Julia, with PostgreSQL and MongoDB, running on AWS EKS with Kubernetes, Terraform and Slurm, plus GROMACS, RDKit and PyTorch for science workloads.
Current work includes scalable algorithms for macromolecular modeling, integrating generative predictive models into its core platform, building a product organization, and expanding a portfolio of drug discovery partnerships.
Deep Origin is headquartered in South San Francisco, California, and hires in the United States and Armenia, currently across engineering, product and sales at senior and director levels.
Other companies in the same industry, closest in size
Deep Origin's technology stack, projects, and hiring signals are inferred from public hiring and company data — career pages, public listings, and company web presence — then clustered and de-duplicated. Figures are estimates that refresh over time. Read our full methodology →
This is not an official vendor or customer list. It is a technology-adoption signal inferred from public data, intended for B2B research.